Background: Although antiretroviral therapy (ART) effectively halts disease progression in
HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges …

Highlights•Broadly neutralizing antibodies are promising for HIV-1 prevention and
therapy.•Newly identified bNAbs reveal novel epitopes and binding modes.•Effective …

Current antiretroviral drug therapies do not cure HIV-1 because they do not eliminate a pool
of long-lived cells harboring immunologically silent but replication-competent proviruses …

Combination antiretroviral therapy (cART) is effective but not curative, and no successful
vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly …

Summary bNAbs may offer advantages over traditional ART for both the prevention and
treatment of HIV-1 infection. In addition, bNAbs may target the latent viral reservoir. bNAb …

Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Antibodies that naturally develop in some individuals infected with human immunodeficiency
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …

An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for
HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the …

The human immunodeficiency virus (HIV) attacks the body's immune system, specifically
CD4+ T-Lymphocytes. The virus gradually takes over the host's immune system, making it …